1 Wang J, Andrae B, Sundstrom K, Ploner A, Strom P, Elfstrom KM, Dillner J and Sparen P: Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in sweden. PLoS Med 14(10): e1002414, 2017.
2 Darlin L, Borgfeldt C, Widen E and Kannisto P: Elderly women above screening age diagnosed with cervical cancer have a worse prognosis. Anticancer Res 34(9): 5147-5151, 2014.
3 Gyllensten U, Lindell M, Gustafsson I and Wilander E: Hpv test shows low sensitivity of pap screen in older women. Lancet Oncol 11(6): 509-510; author reply 510-501, 2010.
4 Hermansson RS, Olovsson M, Hoxell E and Lindstrom AK: Hpv prevalence and hpv-related dysplasia in elderly women. PLoS One 13(1): e0189300, 2018.
5 Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M and Waterboer T: Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44(2): 504-512, 2006.
6 Soderlund-Strand A, Carlson J and Dillner J: Modified general primer pcr system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 47(3): 541-546, 2009.
7 Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr., Young N, Forum Group M and Bethesda W: The 2001 bethesda system: Terminology for reporting results of cervical cytology. JAMA 287(16): 2114-2119, 2002.
8 Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC and Members of LPWG: The lower anogenital squamous terminology standardization project for hpv-associated lesions: Background and consensus recommendations from the college of american pathologists and the american society for colposcopy and cervical pathology. J Low Genit Tract Dis 16(3): 205-242, 2012.
9 Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ and International Agency for Research on Cancer Multicenter Cervical Cancer Study G: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6): 518-527, 2003.
10 Sahlgren H, Elfstrom KM, Lamin H, Carlsten-Thor A, Eklund C, Dillner J and Elfgren K: Colposcopic and histopathologic evaluation of women with hpv persistence exiting an organized screening program. Am J Obstet Gynecol, 2019.
11 Gustafsson L, Sparen P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R and Adami HO: Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer 63(6): 804-809, 1995.
12 Goodman S, Mody RR, Coffey D, Gorman BK, Luna E, Armylagos D, Schwartz MR, Mody DR and Ge Y: Negative pap tests in women with high-grade cervical lesions on follow-up biopsies: Contributing factors and role of human papillomavirus genotyping. Diagn Cytopathol 46(3): 239-243, 2018.
13 Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schunemann H, Paraskevaidis E and Arbyn M: Cytology versus hpv testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 8(CD008587, 2017.
14 Sherman ME, Schiffman M, Cox JT and Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study G: Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (alts). J Natl Cancer Inst 94(2): 102-107, 2002.
15 Johansson H, Bjelkenkrantz K, Darlin L, Dilllner J and Forslund O: Presence of high-risk hpv mrna in relation to future high-grade lesions among high-risk hpv DNA positive women with minor cytological abnormalities. PLoS One 10(4): e0124460, 2015.
16 Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R and Burk RD: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in guanacaste, costa rica. J Infect Dis 191(11): 1808-1816, 2005.
17 Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, Poole C and Smith JS: Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. Int J Cancer 133(6): 1271-1285, 2013.
18 Wu MZ, Li WN, Cha N, Tian LX, Zhang YI, Wu X, Guo KJ and Wu GP: Diagnostic utility of hpv16 e6 mrna or e7 mrna quantitative expression for cervical cells of patients with dysplasia and carcinoma. Cell Transplant 27(9): 1401-1406, 2018.
19 Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikstrom I and Wilander E: Short-time repeat high-risk hpv testing by self-sampling for screening of cervical cancer. Br J Cancer 105(5): 694-697, 2011.
20 Forslund O, Miriam Elfstrom K, Lamin H and Dillner J: Hpv-mrna and hpv-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. Int J Cancer 144(5): 1073-1081, 2019.
21 Cook DA, Smith LW, Law JH, Mei W, Gondara L, van Niekerk DJ, Ceballos KM, Jang D, Chernesky M, Franco EL, Ogilvie GS, Coldman AJ and Krajden M: Comparative performance of human papillomavirus messenger rna versus DNA screening tests at baseline and 48 months in the hpv focal trial. J Clin Virol 108(32-37, 2018.
22 Zorzi M, Del Mistro A, Giorgi Rossi P, Laurino L, Battagello J, Lorio M, Solda M, Martinotti Gabellotti E, Maran M, Dal Cin A, Fiore A, Rugge M and Maggino T: Risk of cin2 or more severe lesions after negative hpv-mrna e6/e7 overexpression assay and after negative hpv-DNA test: Concurrent cohorts with a 5-year follow-up. Int J Cancer, 2019.
23 Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ and Berkhof J: Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the netherlands. BMJ 355(i4924, 2016.
24 Iftner T, Neis KJ, Castanon A, Landy R, Holz B, Woll-Herrmann A, Iftner A, Staebler A, Wallwiener D, Hann von Weyhern C, Neis F, Haedicke-Jarboui J, Martus P, Brucker S, Henes M and Sasieni P: Longitudinal clinical performance of the rna-based aptima human papillomavirus (ahpv) assay in comparison to the DNA-based hybrid capture 2 hpv test in two consecutive screening rounds with a 6-year interval in germany. J Clin Microbiol 57(1), 2019.
25 Burger EA, Kornor H, Klemp M, Lauvrak V and Kristiansen IS: Hpv mrna tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecol Oncol 120(3): 430-438, 2011.
26 Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R and Peto J: Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 Suppl 5(F88-99, 2012.
27 Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL and Monsonego J: The aptima hpv assay versus the hybrid capture 2 test in triage of women with asc-us or lsil cervical cytology: A meta-analysis of the diagnostic accuracy. Int J Cancer 132(1): 101-108, 2013.
28 Guardado-Estrada M, Juarez-Torres E, Roman-Bassaure E, Medina-Martinez I, Alfaro A, Benuto RE, Dean M, Villegas-Sepulveda N and Berumen J: The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer. PLoS One 9(10): e109406, 2014.
29 Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M and Schiffman M: Population-based study of human papillomavirus infection and cervical neoplasia in rural costa rica. J Natl Cancer Inst 92(6): 464-474, 2000.
30 Bergengren L, Lillsunde-Larsson G, Helenius G and Karlsson MG: Hpv-based screening for cervical cancer among women 55-59 years of age. PLoS One 14(6): e0217108, 2019.
31 Agorastos T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, Skenderi A, Lekka I, Koch I, Soutschek E, Boecher O, Kilintzis V, Angelidou S, Katsiki E, Hagemann I, Boschetti Gruetzmacher E, Tsertanidou A, Angelis L, Maglaveras N and Jansen-Duerr P: Human papillomavirus e7 protein detection as a method of triage to colposcopy of hpv positive women, in comparison to genotyping and cytology. Final results of the pipavir study. Int J Cancer 141(3): 519-530, 2017.
32 Luttmer R, Berkhof J, Dijkstra MG, van Kemenade FJ, Snijders PJ, Heideman DA and Meijer CJ: Comparing triage algorithms using hpv DNA genotyping, hpv e7 mrna detection and cytology in high-risk hpv DNA-positive women. J Clin Virol 67(59-66, 2015.